[go: up one dir, main page]

McChargue et al., 2002 - Google Patents

Effect of non-nicotinic moist snuff replacement and lobeline on withdrawal symptoms during 48-h smokeless tobacco deprivation

McChargue et al., 2002

View PDF
Document ID
11290336850097779688
Author
McChargue D
Collins F
Cohen L
Publication year
Publication venue
Nicotine & tobacco research

External Links

Snippet

The present study investigated the effects of two herbal components (BACCOFF™ and DIPSTOP™) of a commercially available smokeless tobacco treatment program for reducing subjective withdrawal symptoms during deprivation. One component, BACCOFF™, is a non …
Continue reading at digitalcommons.unl.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/34—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a carbocyclic ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B13/00—Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES
    • A24F47/00—Smokers' requisites not provided for elsewhere, e.g. devices to assist in stopping or limiting smoking
    • A24F47/002—Simulated smoking devices, e.g. imitation cigarettes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SMOKERS' REQUISITES
    • A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
    • A24D1/00—Cigars; Cigarettes
    • A24D1/002—Cigars; Cigarettes with additives, e.g. for flavouring

Similar Documents

Publication Publication Date Title
Tonnesen et al. A double-blind trial of a nicotine inhaler for smoking cessation
Henningfield et al. Effects of ethanol on cigarette smoking by volunteers without histories of alcoholism
Schneider et al. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial
Rose et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone
McNeill et al. Cigarette withdrawal symptoms in adolescent smokers
Winger et al. A handbook on drug and alcohol abuse: the biomedical aspects
Bohadana et al. Gender differences in quit rates following smoking cessation with combination nicotine therapy: influence of baseline smoking behavior
Fagerström et al. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker?
Buchhalter et al. Tobacco abstinence symptom suppression: the role played by the smoking‐related stimuli that are delivered by denicotinized cigarettes
Hughes et al. Effect of nicotine on the tobacco withdrawal syndrome
Schuh et al. Nicotine nasal spray and vapor inhaler: abuse liability assessment
Gross et al. Nicotine-containing versus de-nicotinized cigarettes: effects on craving and withdrawal
Hatsukami et al. Treatment of spit tobacco users with transdermal nicotine system and mint snuff.
Breland et al. Evaluating acute effects of potential reduced-exposure products for smokers: clinical laboratory methodology
West et al. Effect of buspirone on cigarette withdrawal symptoms and short-term abstinence rates in a smokers clinic
Henningfield et al. Smokeless tobacco: an addicting drug
Nemeth-Coslett et al. Nicotine gum: dose-related effects on cigarette smoking and subjective ratings
Brauer et al. Naltrexone blockade of nicotine effects in cigarette smokers
Maloney et al. Abuse liability assessment of an electronic cigarette in combustible cigarette smokers.
Brauer et al. Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes
Becker et al. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation
Buchhalter et al. Preliminary evaluation of a novel smoking system: effects on subjective and physiological measures and on smoking behavior
Hatsukami et al. Smokeless tobacco abstinence effects and nicotine gum dose
MacLean et al. The effects of inhaled flavors on intravenous nicotine.
Houtsmuller et al. Flavor improvement does not increase abuse liability of nicotine chewing gum